

World Journal of Clinical Cases

RE: Manuscript “Ischemic colitis after receiving the second dose of COVID-19 inactivated vaccine: Case report”

Dear editor:

“Ischemic colitis after receiving the second dose of a COVID-19 inactivated vaccine: A case report”. **We would like to thank World Journal of Clinical Cases** for giving us an opportunity to revise the manuscript. We have carefully taken the comments into consideration in preparing the revised version. The point-by-point responses are presented after this letter. The revisions were highlighted with tracked changes.

The manuscript has not been published previously, in any language, in whole or in part, and is not currently under consideration elsewhere. None of the authors have any competing financial interest to report.

Thank you for considering our manuscript for publication in your prestigious journal.

Point-By-Point Responses

Reviewer #1:

General comments: Present case report is interesting. But author need to address the following question in revised manuscript before acceptance

Response: On behalf of all co-authors, I would like to appreciate for thoughtful comments presented by reviewers. After revision of the manuscript, those significant issues could be eliminated.

Question 1: Place of belongingness of A 48-year-old woman was not discussed In manuscript

Response: Thanks for your suggestion, and the belongingness of the case has been provided in the revised manuscript.

Question 2: Is such observation also reported from other part of world? Mention

Response: Thanks for your comment. The following sentence has been mentioned in the Discussion section: “The present study, for the first time, reported a women who

experienced ischemic colitis after administration of a second dose of the COVID-19 inactivated vaccine”.

Question 3: What is your opinion to get such kind of symptom in person with inactivated vaccine?

Response: Thanks for your valuable comment. The following sentence has been mentioned in the Discussion section: “Therefore, the inactivated vaccine should be applied against COVID-19 owing to the extremely low incidence of ischemic colitis. ”

Question 4: Mention the illness of such women after getting 1st dose if any?

Response: Thanks for your comment. No previous study has reported adverse events for ischemic colitis related to the COVID-19 inactivated vaccines.

Question 5: Did such pattern report with recombinant vaccine also?

Response: Thanks for your comment. No previous study has reported adverse events for ischemic colitis related to the COVID-19 vaccines.

Question 6: Though potential mechanism behind the development of ischemic colitis is not decipher but what would be the probable mechanism of it in your view

Response: Thanks for this comment, and the probable mechanism has been mentioned in the Discussion section.

Question 7: Minor language polishing is needed.

Response: Thanks for this comment, and the manuscript was edited by a prestigious company working on English editing services.

Reviewer #2:

General comments: The case report by Dr. Cui et al. reported a female ischemic colitis case after COVID-19 inactivated vaccine administration in China. It is crucial to identify the adverse event associated with COVID-19 vaccines. This report provides clinical information and plausible mechanisms of ischemic colitis as potential complications of COVID-19 inactivated vaccines. However, there are several comments that deserve attention.

Response: On behalf of all co-authors, I would like to appreciate for thoughtful comments presented by reviewers. After revision of the manuscript, those significant issues could be eliminated.

Question 1: Please change the “COVID-19 epidemic” into “COVID-19 pandemic” where it applies

Response: Thanks for this comment. “COVID-19 epidemic” has been changed into “COVID-19 pandemic” in the revised manuscript.

Question 2: Page 4, line 16: should be “mRNA” instead of “RNA”

Response: Thanks for this comment, and “RNA” has been changed into “mRNA” in the revised manuscript.

Question 3: Critical clinical information is missing, including BMI (or weight and height), menopausal status, medications, and comorbidities. Page 5, line 13 “A previous physical examination found that she had hyperlipidemia, for which she did not receive treatment, and defecation was generally normal.” Please clarify if this single piece of medical record is the only source of all the clinical information of this patient. If there are any self-reported diseases or use of medications before and peri-admission? SBP 140 mmHg is at the threshold of high blood pressure. If this patient has high blood pressure or is currently taking medications also needs to be clarified

Response: Thanks for this comment. The BMI, menopausal status, medications, and comorbidities have been mentioned in the revised manuscript.

Question 4: Page 5, line 11: please avoid using “unremarkable”, which is inappropriate for scientific writing. Detailed information on the patient’s diet history should be provided if available.

Response: Thanks for this comment, and this sentence has been revised as “The patient’s diet history was normal and she did not experience adverse events after receiving the first dose of COVID-19 inactivated vaccine”.

Question 5: Page 6, line 26-28: sentence needs to be rephased

Response: Thanks for your comment, and this sentence has been edited in the revised manuscript.

Question 6: Page 7, line 14-15: sentence needs to be rephased

Response: Thanks for your comment, and this sentence has been edited in the revised manuscript.

Question 7: Page 7, line 22-23: again, “unremarkable” should be avoided

Response: Thanks for your comment We removed “unremarkable” in the revised manuscript.

Question 8: A paragraph summarizing the clinical presentation and etiologies of ischemic colitis could be added before the discussion about its potential linkage with COVID vaccine.

Response: Thanks for your comment. The presentation and etiologies of ischemic colitis have already been discussed in the revised manuscript.

Reviewer #3:

General comments: In the current pandemic situation in Covid-19 where every medical professional is struggling to help find a cure for this scourge, the advent of vaccines came as a relief to the community.

Therefore, the subject matter is still relevant today as any adverse events attributable to the covid-19 vaccine must be reported and scientifically proven.

Response: On behalf of all co-authors, I would like to appreciate for thoughtful comments presented by reviewers. After revision of the manuscript, those significant issues could be eliminated.

Question 1: We know that the management of the patient is the task of a multidisciplinary team.

Could you explain why the article has only 3 authors?

Response: Thanks for your comment. We are aware of the point that the management of the patient is the task of a multidisciplinary team, however, only 3 authors contributed to this study.

Question 2: In the abstract, there is confusion between conclusion and the aim of the article.

Can you redo it refer to the 2016 CARE checklist criteria?

Conclusion is a take home lesson when reading your article. You concluded that the

mechanism is not clear but you were able to establish the causal relationship between the vaccine and the occurrence of ischemic colitis. Please, can you convince us, especially since there is no hemostasis or lipid profile with non-elevated D-dimer on how you were able to eliminate other causes of ischemic colitis? Briefly, you could redo the conclusion and give detailed hemostasis and lipid assessment.

Response: Thanks for your comment. The conclusion section has been revised as “We reported a case of ischemic colitis after administration of the second dose of the COVID-19 inactivated vaccine. Thus, the occurrence of ischemic colitis should be considered after administration of the COVID-19 inactivated vaccines.”

Question 3: Can you enlighten us on how you knew and concluded that the vaccine was the cause of ischemic colitis?

Response: Thanks for your comment, and the following sentence has been edited in the revised manuscript: “The onset time of ischemic colitis was closely correlated to the administration of the COVID-19 vaccines, and a potential association could not be ruled out”

Question 4: Covid-19 is a pandemic (could you correct where written epidemic by pandemic)

Response: Thanks for your comment, and “COVID-19 epidemic” has been changed into “COVID-19 pandemic” in the revised manuscript.

Question 5: Could you specify the injection site of the vaccine?

Response: Thanks for your comment, and the injection site of the vaccine has been mentioned in the revised manuscript.

Question 6: Discuss other possible side effects of the covid-19 vaccine if any

Response: Thanks for your comment, and other possible side effects of the covid-19 vaccine have been mentioned in the second paragraph of the Discussion section.

Question 7: In conclusion, can you suggest the treatment used as a preventive remedy after the covid-19 vaccines? because prevention is better than cure

Response: Thanks for your comment. The following sentence was added into the Conclusion section: “Patients with abdominal pain accompanied by hematochezia at 1 day after administration of COVID-19 inactivated vaccines should be cautiously

managed in clinical practice.”

Question 8: Put the acknowledgements before the references if any

Response: Thanks for your comment, and the acknowledgements have been mentioned before the references.

Question 9: Put the figures in a separate document

Response: Thanks for your comment. Figures have been uploaded as a separate document.

Science Editor:

General comments: The case reports a possible a possible relationship between ischemic colitis and Covid-19 vaccine. The subject of adverse events attributable to the covid-19 vaccine is relevant for the medical community. All the reviewers agree that the case should be published with minor revisions. More data on the clinical and personal history should be provided. A more deepened discussion on the possible mechanism of IC after the second dose of the vaccine should be added.

Language Quality: Grade B (Minor language polishing)

Scientific Quality: Grade B (Very good)

Response: On behalf of all co-authors, I would like to appreciate for thoughtful comments presented by reviewers. After revision of the manuscript, those significant issues could be eliminated. First, additional clinical and general data have been mentioned in the revised manuscript. Moreover, the possible mechanism of IC after the second dose of the vaccine has been discussed in the revised manuscript.

Company editor-in-chief:

General comments: I have reviewed the Peer-Review Report, full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the World Journal of Clinical Cases, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office’s comments and the Criteria for Manuscript Revision by Authors. Please provide the original figure documents. Please prepare and

arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor.

Response: On behalf of all co-authors, I would like to appreciate for thoughtful comments presented by reviewers. After revision of the manuscript, those significant issues could be eliminated. Moreover, the original figure documents have been provided in a PowerPoint file.